Acura Pharmaceuticals
OTCMKTS:ACURAcura Pharmaceuticals, Inc., an innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc. and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide; and development and commercialization agreement with Abuse Deterrent Pharma, LLC to develop LTX-03, an immediate-release tablets utilizing LIMITx technology. The company was formerly known as Halsey Drug Co., Inc. The company was incorporated in 1935 and is based in Palatine, Illinois. Acura Pharmaceuticals, Inc. operates as a subsidiary of Abuse Deterrent Pharma, LLC.
Mateon Therapeutics
OTCMKTS:MATNMateon Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma. The company is headquartered in Agoura Hills, California.
Nuvo Pharmaceuticals
OTCMKTS:MRVFFNuvo Pharmaceuticals, Inc. is a pharmaceutical company, which is engaged in developing innovative therapeutic pharmaceutical products. It operates through the following segments: Commercial Business, Production and Service Business, and Licensing and Royalty Business. The Commercial Business segment includes Blexten, Cambia, the canadian business for Resultz and Suvexx, and mature assets. The Production and Service Business segment supplies Pennsaid to Horizon for the U.S. market and is engaged in ongoing partnering efforts for Pennsaid. The Licensing and Royalty Business segment engages in the selling of Vimovo. The company was founded on August 22, 1983 and is headquartered in Mississauga, Canada.
Nuvo Pharmaceuticals
OTCMKTS:NRIFFNuvo Pharmaceuticals, Inc. is a pharmaceutical company, which is engaged in developing innovative therapeutic pharmaceutical products. It operates through the following segments: Commercial Business, Production and Service Business and Licensing and Royalty Business. The Commercial Business segment includes Blexten, Cambia, the canadian business for Resultz and Suvexx, and mature assets. The Production and Service Business segment supplies Pennsaid to Horizon for the U.S. market and is engaged in ongoing partnering efforts for Pennsaid. The Licensing and Royalty Business segment engages in the selling of Vimovo. Nuvo Pharmaceuticals was founded on August 22, 1983 and is headquartered in Mississauga, Canada.
Intec Pharma
NASDAQ:NTECIntec Pharma Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of drugs based on proprietary Accordion Pill platform technology. Its Accordion Pill technology is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs under development by utilizing an efficient gastric retention and specific release mechanism. The company was founded by Zvika Joseph on October 23, 2000 and is headquartered in Jerusalem, Israel.